WALTHAM, Mass., Nov. 4 /PRNewswire-FirstCall/ -- Repligen Corporation
(Nasdaq: RGEN) announced today that the Company President and Chief Executive
Officer, Walter C. Herlihy, Ph.D., will speak at the Rodman & Renshaw Techvest
7th Annual Healthcare Conference on Tuesday, November 8th, 2005 at 10:50 A.M.
EST at the New York Palace Hotel, Madison Avenue at 50th, New York, New York.
A live audio-webcast of the presentation will be available at
http://www.wsw.com/webcast/rrshq7/rgen/ and will be archived for 30 days
following the presentation. The presentation may also be accessed via
Repligen's website at http://www.repligen.com.
About Repligen Corporation
Repligen Corporation is a biopharmaceutical company committed to being the
leader in the development of novel therapeutics for profound neuropsychiatric
disorders and autoimmune disease. Repligen has a Specialty Pharmaceuticals
business comprised of rProtein A(TM) and SecreFlo(R), the profits from which
will be used to partially support the development of our proprietary products.
Repligen's corporate headquarters are located at 41 Seyon Street, Building #1,
Suite 100, Waltham, MA 02453. Additional information may be requested from
http://www.repligen.com.
This release contains forward-looking statements which are made pursuant
to the safe harbor provisions of Section 21E of the Securities Exchange Act of
1934. The forward-looking statements in this release do not constitute
guarantees of future performance. Investors are cautioned that statements in
this press release which are not strictly historical statements, including,
without limitation, statements regarding current or future financial
performance, management's strategy, plans and objectives for future
operations, clinical trials and results and product development and
manufacturing plans and performance such as the anticipated growth in the
monoclonal antibody market and projected growth in product sales, constitute
forward-looking statements. Such forward-looking statements are subject to a
number of risks and uncertainties that could cause actual results to differ
materially from those anticipated, including, without limitation, risks
associated with: the success of current and future collaborative
relationships, the market acceptance of our products, our ability to compete
with larger, better financed pharmaceutical and biotechnology companies, new
approaches to the treatment of our targeted diseases, our expectation of
incurring continued losses, our uncertainty of product revenues and profits,
our ability to generate future revenues, our ability to raise additional
capital to continue our drug development programs, the success of our clinical
trials, our ability to develop and commercialize products, our ability to
obtain required regulatory approvals, our compliance with all Food and Drug
Administration regulations, our ability to obtain, maintain and protect
intellectual property rights for our products, the risk of litigation
regarding our intellectual property rights, our limited sales and
manufacturing capabilities, our dependence on third-party manufacturers and
value added resellers, our ability to hire and retain skilled personnel, our
volatile stock price, and other risks detailed in Repligen's filings with the
Securities and Exchange Commission. Repligen assumes no obligation to update
any forward-looking information contained in this press release or with
respect to the announcements described herein.
SOURCE Repligen Corporation
 back to top
Related links:
http://www.repligen.com
CONTACT:
Walter C. Herlihy, Ph.D., President and Chief
Executive Officer, +1-781-250-0111, ext. 2000, or Laura
Whitehouse, Vice President, Market Development, +1-781-250-0111,
ext. 2306, both of Repligen Corporation
|
